Supercharged immune cells take on Hard-to-Treat lung cancer
NCT ID NCT05681780
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new approach for people with advanced non-small cell lung cancer that has specific gene changes (EGFR, ALK, ROS1, or HER2). Doctors take immune cells from the patient's own tumor, boost them in the lab with a molecule called CD40L, and then give them back along with the immunotherapy drug nivolumab. The goal is to see if this combination is safe and can shrink tumors. The study is currently recruiting 20 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tumor-infiltrating lymphocytes (TIL) boosted with CD40L, plus nivolumab (Opdivo), cyclophosphamide, and fludarabine
What this could lead to
If it works, this could point toward a new treatment option for people with advanced lung cancer that has specific gene changes and has stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 20 participants, so it is primarily testing safety, not effectiveness. The treatment involves strong chemotherapy and immune therapy, which can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••